Zoom Press Event in Advance of Nov 4-8 Conference
–(BUSINESS WIRE)–#AASLD—
WHAT
To highlight newest cutting-edge research on liver disease, the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® (TLM®) will hold a virtual news conference Wednesday, November 2 at 12noon Eastern. The news briefing features four experts discussing their conference sessions to be presented during TLM November 4-8, 2022, in Washington, D.C.
TLM features hundreds of NEW abstracts and poster sessions with the top minds in hepatology discussing topics covering every disease state including NAFLD, NASH, and hepatitis. Leading hepatologists and public health experts from across the globe will share their thoughts on the effects of the COVID-19 virus from both clinical and public health perspectives. The virtual news conference is a way to provide a sneak peek of TLM to journalists.
VIRTUAL PRE-BRIEF HIGHLIGHTED SESSIONS
- IMPACT OF THE COVID-19 PANDEMIC ON MORTALITY RATE OF LIVER DISEASE IN THE UNITED STATES: A POPULATION-BASED STUDY, 2010-2021. Age-standardized mortality rates for alcohol-related liver disease and nonalcohol fatty liver disease increased at alarming rates during the COVID-19 pandemic with the largest disparities among the young, non-Hispanic white, non-Hispanic black, and Alaska Indian/Native American populations. Yee Hui Yeo, Cedars-Sinai Medical Center, Division of General Internal Medicine, Los Angeles.
- INTEGRATION OF WEIGHT MANAGEMENT CARE FOR NONALCOHOLIC FATTY LIVER DISEASE IMPROVES REFERRALS TO BARIATRIC SURGERY. A multidisciplinary NAFLD program enabled more referrals for bariatric surgery at a rate 25 times higher than the national average. Given the known efficacy of bariatric surgery to treat NAFLD, this may be a model for multidisciplinary NAFLD care. Integrating weight management care to hepatology programs may benefit patients with NAFLD. Ysabel Ilagan-Ying, Department of Internal Medicine, Yale University School of Medicine, and West Haven Veterans Medical Center, CT.
- THE INCREASE IN ALCOHOL-RELATED HEPATITIS CASES DURING THE COVID-PANDEMIC: IS IT A NEW NORMAL? Alcohol-related hepatitis is associated with significant morbidity, mortality, and societal cost. The study revealed that the admissions for alcohol-related hepatitis remained significantly above the pre-pandemic levels through the end of 2021. This sustained increase in cases of alcohol-related hepatitis at a hospital system, may be reflective of a much larger national problem. Urgent public health interventions are needed at a national level to prevent this rise in cases from becoming a new normal. Aalam Sohal, Internal Medicine, UCSF Fresno; and Department of Internal Medicine, University of California, San Francisco – Fresno.
- UNDER-REPRESENTATION OF RACIAL AND ETHNIC MINORITIES IN CIRRHOSIS CLINICAL TRIALS. Black and Latino patients are substantially under-represented in clinical trials of patients with cirrhosis. There was significant underreporting of race and ethnicity of participants in cirrhosis random clinical trials. Barriers to clinical trial enrollment of racial and ethnic minority patients with cirrhosis should be systematically investigated to improve representation. Nneka Ufere, Massachusetts General Hospital, Boston.
WHEN
Wednesday, November 2, 2022, 12noon Eastern.
WHY
The American Association for the Study of Liver Disease holds The Liver Meeting® for 10,000 attendees to obtain data on the newest cutting-edge scientific research on hepatology. Leading experts from across the globe come together for this meeting to present NEW scientific research.
HOW
Journalists may confirm participation in the virtual sneak peek by registering for Zoom meeting at: https://us02web.zoom.us/j/85153846101?pwd=ZXZ4Y3JUYVdMbzhydW5nd0IwVXp5dz09.
Contacts
Sheri Singer, 703-346-7111
